ATC161 exposure and alpha-synuclein aggregate degradation
A reduced AUTOTAC PK/PD model linking ATC161 exposure to concentration-dependent degradation and recovery of alpha-synuclein aggregates.
- Therapeutic
- ATC161
- Target
- alpha-synuclein aggregates, SNCA aggregates, p62, SQSTM1
- Disease
- Preclinical Parkinson disease and synucleinopathy models
Biological model
A reduced AUTOTAC PK/PD model linking ATC161 exposure to concentration-dependent degradation and recovery of alpha-synuclein aggregates.
Intervention
ATC161
Biological focus
alpha-synuclein aggregates, SNCA aggregates, p62, SQSTM1
Context
Preclinical Parkinson disease and synucleinopathy models
Model details
A reduced AUTOTAC PK/PD model linking ATC161 exposure to concentration-dependent degradation and recovery of alpha-synuclein aggregates.
Modeled states
- aggregate fractiondimensionless
Modeled dynamic state for aggregate fraction.
- auc atc161 h ng mLh*ng/mL
Modeled dynamic state for auc atc161 h ng ml.
- plasma atc161 ng mLng/mL
Modeled dynamic state for plasma atc161 ng ml.
Key readouts
- Plasma ATC161ng/mL
Model-derived readout for plasma atc161.
- ATC161 molar concentrationunknown
Model-derived readout for atc161 molar concentration.
- Aggregate degradation effectunknown
Model-derived readout for aggregate degradation effect.
- Alpha-synuclein aggregate fractiondimensionless
Model-derived readout for alpha-synuclein aggregate fraction.
- atc161 dc50 ng mLunknown
Model-derived readout for atc161 dc50 ng ml.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
PO 20 mg/kg first-order PK/degradation
How does ATC161 exposure control the time course and recovery of alpha-synuclein aggregate reduction? Explore this biological starting configuration through Plasma ATC161, ATC161 molar concentration, Aggregate degradation effect, Alpha-synuclein aggregate fraction. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How does ATC161 exposure control the time course and recovery of alpha-synuclein aggregate reduction?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How does ATC161 exposure control the time course and recovery of alpha-synuclein aggregate reduction?
atc161 po half life h
Model parameter controlling atc161 po half life h.
Exploratory range around the default value.
5 evenly spaced values in h. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technologyMolecular Neurodegeneration
